Michael F Cola
CIK 1188940 · Chief Executive Officer · last filed 2026-05-21
Michael F Cola is a Chief Executive Officer who has filed 69 SEC Form 4 insider transactions across 9 companies since 2011. The most recent filing, for PHAT, was dated May 21, 2026. Across all open-market trades the lifetime net is +$1.4M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $84.1M across reported positions. 11 SEC filings were submitted jointly with Cerecor Inc.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
MDGN.WS price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
WAYNE, PA 19087-1945
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PHAT | Director | 63,920 | $5.94 | $379.7K | $186.2K | 8 | 2026-05-21 |
| Sage Therapeutics, Inc. (SAGE) Delisted | Director | — | $8.68 | — | $0 | 13 | 2025-07-31 |
| AVTX | Chief Executive Officer | — | $6.77 | — | $0 | 1 | 2021-10-04 |
| Avalo Therapeutics, Inc. (CERC) Delisted | Chief Executive Officer | 175,746 | $2.93 | $514.9K | $250.0K | 9 | 2021-07-02 |
| GNMX | President and CEO | 2,267,859 | $36.79 | $83.44M | $424.6K | 7 | 2019-12-09 |
| VNDA | Director | 15,000 | $3.94 | $59.1K | $0 | 7 | 2019-06-17 |
| Aevi Genomic Medicine, LLC (MDGN) Delisted | President and CEO | — | — | — | $0 | 1 | 2016-04-19 |
| Aevi Genomic Medicine, LLC (MDGN.WS) Delisted | President and CEO | 99,436 | — | — | $500.0K | 4 | 2015-10-08 |
| PATH | Director | 13,500 | $14.30 | $193.1K | $0 | 16 | 2014-01-03 |
Recent Filings
69 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-05-21 | PHAT | Grant (A) | +24,122 | $0 | EDGAR |
| 2025-07-31 | Sage Therapeutics, Inc. (SAGE) Delisted | Disp (D) | — | $0 | EDGAR |
| 2025-06-13 | Sage Therapeutics, Inc. (SAGE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2025-06-05 | PHAT | Grant (A) | +10,500 | $0 | EDGAR |
| 2024-06-11 | Sage Therapeutics, Inc. (SAGE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-05-24 | PHAT | Grant (A) | +10,500 | $0 | EDGAR |
| 2023-06-16 | Sage Therapeutics, Inc. (SAGE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-05-30 | PHAT | Grant (A) | +9,000 | $0 | EDGAR |
| 2022-06-17 | Sage Therapeutics, Inc. (SAGE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-05-27 | PHAT | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.